脑转移瘤的免疫治疗联合立体定向体部放射治疗或全脑放射治疗。
Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases.
机构信息
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
出版信息
Immunotherapy. 2023 Feb;15(3):163-174. doi: 10.2217/imt-2022-0051. Epub 2023 Feb 7.
To investigate the association of stereotactic radiation therapy (SRT) or whole-brain radiation therapy (WBRT) plus immunotherapy with the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer. Patients diagnosed with BMs were identified from the National Cancer Database. A total of 34,286 patients were included. SRT plus immunotherapy was associated with improved OS compared with SRT without immunotherapy (hazard ratio: 0.774; 95% CI: 0.687-0.872; p < 0.001), and WBRT plus immunotherapy was associated with improved OS compared with WBRT without immunotherapy (hazard ratio: 0.724; 95% CI; 0.673-0.779; p < 0.001). SRT plus immunotherapy was associated with improved OS compared with SRT. WBRT plus immunotherapy was associated with improved OS compared with WBRT in cancer patients who had BMs at the time of primary cancer diagnosis.
为了调查立体定向放射治疗（SRT）或全脑放射治疗（WBRT）加免疫治疗与脑转移（BMs）癌症患者的总生存（OS）的关联，无论原发性癌症如何。从国家癌症数据库中确定了患有 BMs 的患者。共纳入 34286 名患者。与未接受免疫治疗的 SRT 相比，SRT 加免疫治疗与改善的 OS 相关（风险比：0.774；95%CI：0.687-0.872；p<0.001），与未接受免疫治疗的 WBRT 相比，WBRT 加免疫治疗与改善的 OS 相关（风险比：0.724；95%CI：0.673-0.779；p<0.001）。与 SRT 相比，SRT 加免疫治疗与改善的 OS 相关。与 WBRT 相比，WBRT 加免疫治疗与改善的 OS 相关，在原发性癌症诊断时患有 BMs 的癌症患者中。
Zotero 插件